A 53-year-old man with a known history of hypertrophic cardiomyopathy underwent implantation of a left-sided dual-chamber pacemaker in 1998 to treat a minimally symptomatic outflow tract gradient. Twelve years later, he developed nonsustained ventricular tachycardia and was referred for an upgrade to an implantable cardioverter defibrillator (ICD) for primary prevention of sudden cardiac death. Ipsilateral venous access was attempted but was not possible due to a chronic total left innominate vein occlusion. Laser lead extraction was then attempted to establish access. Despite extensive delivery of laser bursts and use of several laser sheaths over both the atrial and ventricular leads, the extraction was unsuccessful due to the presence of significantly calcified scar tissue at the level of the subclavian-clavicular junction. Because the patient had normal underlying conduction and had not required any pacing (right atrial and right ventricular pacing both Ͻ1%), the pacemaker leads were abandoned. In an effort to avoid implantation of a new transvenous ICD lead and pulse generator on the contralateral side, a totally subcutaneous ICD (S-ICD, Cameron Health, Inc., San Clemente, Calif) was implanted through a left inframammary incision ( Figure 1A) . Dissection was carried out perpendicular to the incision down to the fascia overlying the rib cage, and a pocket was created. A tunneling tool was then used to tunnel the lead subcutaneously from the device pocket to the region of the xyphoid process and then up to the sternal-manubrium junction at the second rib (angle of Louis) parallel to the left sternal border. The insertion of the subcutaneous ICD was guided exclusively by anatomic landmarks; no fluoroscopy was required. Postoperative posteroanterior ( Figure 1B ) and lateral ( Figure 1C ) chest radiographs show the position of the device and shocking electrode relative to the abandoned pacing leads. The patient had appropriate detection and 2 successful consecutive terminations of induced ventricular fibrillation, with subcutaneous shocks of 65 J. The standard and final programmed output of shock energy delivered by the subcutaneous ICD is 80 J. Human implantation of the subcutaneous ICD is approved as an investigational device exception in the United States and marketed internationally. It has been shown to consistently detect and convert ventricular fibrillation in small, nonrandomized studies. 1 This novel system will further simplify defibrillator use in ICD-indicated populations that do not require pacing by avoiding chronic transvenous lead placement.
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